中国神经再生研究(英文版) ›› 2017, Vol. 12 ›› Issue (2): 193-196.doi: 10.4103/1673-5374.200795

• 综述:脑损伤修复保护与再生 • 上一篇    下一篇

Toll样受体4可作为动脉瘤蛛网膜下出血后延迟脑损伤的可能治疗靶标

  

  • 收稿日期:2017-02-20 出版日期:2017-02-15 发布日期:2017-02-15
  • 基金资助:

     

    这项研究得到了三重县医学研究基金会对铃木博士的科学研究资助。

Toll-like receptor 4 as a possible therapeutic target for delayed brain injuries after aneurysmal subarachnoid hemorrhage

Takeshi Okada, Hidenori Suzuk   

  1. Department of Neurosurgery, Mie University Graduate School of Medicine, Tsu, Japan
  • Received:2017-02-20 Online:2017-02-15 Published:2017-02-15
  • Contact: Hidenori Suzuki, M.D., Ph.D., suzuki02@clin.medic.mie-u.ac.jp.
  • Supported by:

    This work was supported by a Grant-in-Aid for Scientific Research from Mie Medical Research Foundation to Dr. Suzuki.

摘要:

 

动脉瘤蛛网膜下腔出血是脑血管疾病中结果最糟糕的神经障碍。动脉瘤蛛网膜下腔出血的治疗已经靶向主要防止导致或加重早期脑损伤的早期阶段的颅内动脉瘤再出血,以及预防或逆转引起迟发性脑损伤的脑血管痉挛。为了克服迟发性脑损伤,需要治疗早期脑损伤以及脑血管痉挛。然而,早期脑损伤和血管痉挛发展的确切分子机制仍然模糊。神经炎症是蛛网膜下腔出血的公认结果,并且可能在蛛网膜下腔出血后造成早期脑损伤,脑血管痉挛和迟发性脑损伤。在颅内动脉瘤破裂后,颅内压突然升高,导致短暂的全脑性脑缺血。全球性脑缺血以及来自蛛网膜下腔出血的红细胞分解产物触发了许多级联,包括炎症反应。 Toll样受体属于在先天免疫和炎症反应中起关键作用的模式识别受体家族。在Toll样受体家族成员中,Toll样受体4在中枢神经系统中的各种细胞类型中表达,包括小胶质细胞,神经元,星形胶质细胞,毛细血管内皮细胞,脑动脉的内皮和平滑肌细胞,以及外周血细胞如白细胞,巨噬细胞和血小板。事实上,具报道,动脉瘤蛛网膜下腔出血患者在外周血单核细胞上具有更高的Toll样受体4水平,其与更大质量的蛛网膜下腔出血,并且与发生脑血管痉挛,脑梗死和更差的功能恢复相关。

ORCID:0000-0002-8555-5448(Hidenori Suzuki)

Abstract:

Neuroinflammation is a well-recognized consequence of subarachnoid hemorrhage (SAH), and Toll-like receptor (TLR) 4 may be an important therapeutic target for post-SAH neuroinflammation. Of the TLR family members, TLR4 is expressed in various cell types in the central nervous system, and is unique in that it can signal through both the myeloid differentiation primary-response protein 88-dependent and the toll receptor associated activator of interferon-dependent cascades to coordinate the maximal inflammatory response. TLR4 can be activated by many endogenous ligands having damage-associated molecular patterns including heme and fibrinogen at the rupture of an intracranial aneurysm, and the resultant inflammatory reaction and thereby tissue damages may furthermore activate TLR4. It is widely accepted that the excreted products of TLR4 signaling alter neuronal functions. Previous studies have focused on the pathway through nuclear factor (NF)-κΒ signaling among TLR4 signaling pathways as to the development of early brain injury (EBI) such as neuronal apoptosis and blood-brain barrier disruption, and cerebral vasospasm. However, many findings suggest that both pathways via NF-κΒ and mitogen-activated protein kinases may be involved in EBI and cerebral vasospasm development. To overcome EBI and cerebral vasospasm is important to improve outcomes after SAH, because both EBI and vasopasm are responsible for delayed brain injuries or delayed cerebral ischemia, the most important preventable cause of poor outcomes after SAH. Increasing evidence has shown that TLR4 signaling plays an important role in SAH-induced brain injuries. Better understanding of the roles of TLR4 signaling in SAH will facilitate development of new treatments.

Key words: cerebral aneurysm;, cerebral vasospasm, early brain injury, delayed brain injury, delayed cerebral ischemia, inflammation, subarachnoid hemorrhage, Toll-like receptor 4